Matthew Sykes
Stock Analyst at Guggenheim
(3.95)
# 478
Out of 4,820 analysts
196
Total ratings
50.37%
Success rate
8.5%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Buy | $140 → $125 | $95.17 | +31.34% | 2 | Apr 29, 2025 | |
| AVTR Avantor | Downgrades: Neutral | $23 → $14 | $12.68 | +10.41% | 6 | Apr 29, 2025 | |
| DHR Danaher | Maintains: Buy | $260 → $240 | $197.76 | +21.36% | 5 | Apr 23, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $17 → $15 | $6.88 | +118.02% | 7 | Apr 17, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $18 → $14 | $7.23 | +93.64% | 11 | Apr 17, 2025 | |
| CDNA CareDx | Maintains: Buy | $34 → $26 | $18.20 | +42.86% | 10 | Apr 17, 2025 | |
| ICLR ICON Public Limited Company | Downgrades: Neutral | $250 → $200 | $146.72 | +36.31% | 3 | Mar 21, 2025 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | $190 → $170 | $116.32 | +46.15% | 4 | Mar 21, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $22 → $11 | $6.22 | +76.99% | 3 | Mar 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $49 → $56 | $48.61 | +15.20% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $115.58 | -30.78% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.12 | +34.53% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $154.00 | +23.38% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.70 | +150.75% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.07 | +105.81% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $31.65 | +16.90% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $60 | $39.78 | +50.83% | 4 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $44.71 | +45.38% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $152.12 | +64.34% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $14 | $8.40 | +66.67% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $55 | $39.38 | +39.68% | 9 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $6.23 | +285.54% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,054.06 | +23.33% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $7.53 | +59.36% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $425.89 | +50.27% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $3.72 | +168.82% | 8 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $107.00 | +35.51% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $42.71 | - | 5 | Dec 7, 2023 |
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $95.17
Upside: +31.34%
Avantor
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $12.68
Upside: +10.41%
Danaher
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $197.76
Upside: +21.36%
NeoGenomics
Apr 17, 2025
Maintains: Buy
Price Target: $17 → $15
Current: $6.88
Upside: +118.02%
Myriad Genetics
Apr 17, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $7.23
Upside: +93.64%
CareDx
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $18.20
Upside: +42.86%
ICON Public Limited Company
Mar 21, 2025
Downgrades: Neutral
Price Target: $250 → $200
Current: $146.72
Upside: +36.31%
Charles River Laboratories International
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $116.32
Upside: +46.15%
Fortrea Holdings
Mar 4, 2025
Maintains: Neutral
Price Target: $22 → $11
Current: $6.22
Upside: +76.99%
Guardant Health
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $48.61
Upside: +15.20%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $115.58
Upside: -30.78%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.12
Upside: +34.53%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $154.00
Upside: +23.38%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.70
Upside: +150.75%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.07
Upside: +105.81%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $31.65
Upside: +16.90%
Dec 5, 2024
Upgrades: Neutral
Price Target: $60
Current: $39.78
Upside: +50.83%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $44.71
Upside: +45.38%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $152.12
Upside: +64.34%
Oct 30, 2024
Maintains: Sell
Price Target: $16 → $14
Current: $8.40
Upside: +66.67%
Jul 9, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $39.38
Upside: +39.68%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $6.23
Upside: +285.54%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,054.06
Upside: +23.33%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $7.53
Upside: +59.36%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $425.89
Upside: +50.27%
Feb 29, 2024
Maintains: Buy
Price Target: $9 → $10
Current: $3.72
Upside: +168.82%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $107.00
Upside: +35.51%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $42.71
Upside: -